Cullinan Therapeutics, Inc.
NASDAQ:CGEMMedical - Pharmaceuticals
+$0.62 today
- Market cap
- $584.94M
- Beta
- 0.01
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$3.73
Volume 1.06M
Average 0.99M
CGEM Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Cullinan Therapeutics, Inc.NASDAQ: CGEM
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 2.1% from a year ago
Cash & equivalents stood at $75.08M at the end of Q1 FY2026, down 2.1% from a year earlier and down 15.0% from the prior quarter. Over 3 fiscal years it compounded at -17.3% a year.
Context
- Cash & equivalents amounted to 18.6% of total assets at the end of Q1 FY2026, up 5.4 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -2.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 88.33M USD
- Year-over-year change
- +6.4%
- 4-year CAGR
- +10.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 88.33M | +6.4% |
| FY2024 | 2024-12-31 | 83.01M | -15.7% |
| FY2023 | 2023-12-31 | 98.43M | -37.0% |
| FY2022 | 2022-12-31 | 156.15M | +161.2% |
| FY2021 | 2021-12-31 | 59.77M | — |
Cash & Equivalents vs competitors
How CGEM compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -2.1% is the 8th highest of 11, against a peer median of +21.4%.
- Cash & equivalents amounts to 18.6% of total assets for CGEM, versus a peer median of 22.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Aug 2026 | $720.24M USD | +818.2% | +56.5% | 60.3% | |
| Sep 2026 | $460.7M USD | +65.2% | +4.7% | 27.4% | |
| Mar 2026 | €301.65M EUR | +24.2% | +32.5% | 55.5% | |
| Mar 2026 | $231.01M USD | +18.6% | -7.1% | 79.2% | |
| Mar 2026 | $75.08M USD | -2.1% | -17.3% | 18.6% | |
| Mar 2026 | $66.52M USD | -54.3% | -19.3% | 30.5% | |
| Mar 2026 | $62.1M USD | +24.5% | -34.7% | 17.8% | |
| Mar 2026 | $51.83M USD | -29.7% | +0.6% | 5.0% | |
| Jun 2026 | $44.66M USD | +0.5% | +0.1% | 6.2% | |
| Mar 2026 | $32.28M USD | +56.6% | -30.5% | 18.1% | |
| Mar 2026 | $12.44M USD | -14.7% | +101.6% | 8.5% | |
| Peer median (excluding CGEM) | — | +21.4% | +0.3% | 22.8% | |
Competitors are the stored peer set for CGEM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 59.77M | 156.15M | 98.43M | 83.01M | 88.33M |
| Short-term Investments | 230.69M | 311.14M | 368.63M | 315.97M | 289.56M |
| Net Receivables | 0 | 0 | 0 | 3M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 7.18M | 13.12M | 12.69M | 8.86M |
| Total Current Assets | 296.56M | 474.47M | 480.19M | 414.67M | 386.76M |
| Property, Plant & Equipment (Net) | 77K | 5.3M | 3.53M | 2.35M | 3.05M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 140.4M | 80.88M | 0 | 204.44M | 58.27M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 147K | 459K | 459K | 366K | 297K |
| Total Non-current Assets | 140.62M | 86.65M | 3.99M | 207.16M | 61.62M |
| Total Assets | 437.19M | 561.12M | 484.18M | 621.82M | 448.37M |
| Account Payables | 3.17M | 2.66M | 2.49M | 1.68M | 841K |
| Short-term Debt | 0 | 178K | 0 | 0 | 0 |
| Tax Payables | 0 | 4.28M | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.55M | 1.96M | 7.9M | 1.44M | 10.95M |
| Total Current Liabilities | 11.75M | 22.5M | 28.14M | 30.65M | 37.74M |
| Long-term Debt | 0 | 0 | 0 | 0 | 1.9M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 65K | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 65K | 3.59M | 2.15M | 849K | 1.9M |
| Total Liabilities | 11.81M | 26.09M | 30.29M | 31.5M | 39.64M |
| Common Stock | 4K | 5K | 4K | 6K | 6K |
| Retained Earnings | (158.91M) | (47.7M) | (200.86M) | (368.24M) | (588.12M) |
| Accumulated OCI | (838K) | (2.6M) | (129K) | (133K) | 1.02M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 403K | 0 | 192K | 0 | 0 |
| Total Equity | 425.37M | 535.03M | 453.9M | 590.33M | 408.73M |
| Total Debt | 0 | 5.19M | 3.59M | 2.15M | 2.68M |
| Net Debt | (59.77M) | (150.96M) | (94.84M) | (80.85M) | (85.65M) |
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
Intrinsic Alpha fair value
Locked
Current Price
$9.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.